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ARTICLE OPEN
De novo large rare copy-number variations contribute
to conotruncal heart disease in Chinese patients
Christopher CY Mak1, Pak Cheong Chow1, Anthony PY Liu1, Kelvin YK Chan2, Yoyo WY Chu1, Gary TK Mok1, Gordon KC Leung1,
Kit San Yeung1, Adolphus KT Chau1, Chelsea Lowther3, Stephen W Scherer4, Christian R Marshall4, Anne S Bassett3
and Brian HY Chung1
Conotruncal heart anomalies (CTDs) are particularly prevalent congenital heart diseases (CHD) in Hong Kong. We surveyed large
(4500 kb), rare (o1% frequency in controls) copy-number variations (CNVs) in Chinese patients with CTDs to identify potentially
disease-causing variations. Adults who tested negative for 22q11.2 deletions were recruited from the adult CHD clinic in Hong
Kong. Using a stringent calling criteria, high-conﬁdence CNV calls were obtained, and a large control set comprising 3,987
Caucasian and 1,945 Singapore Chinese subjects was used to identify rare CNVs. Ten large rare CNVs were identiﬁed, and 3 in 108
individuals were conﬁrmed to harbour de novo CNVs. All three patients were syndromic with a more complex phenotype, and
each of these CNVs overlapped regions likely to be important in CHD. One was a 611 kb deletion at 17p13.3, telomeric to the
Miller–Dieker syndrome (MDS) critical region, overlapping the NXN gene. Another was a 5 Mb deletion at 13q33.3, within a
previously described critical region for CHD. A third CNV, previously unreported, was a large duplication at 2q22.3 overlapping the
ZEB2 gene. The commonly reported 1q21.1 recurrent duplication was not observed in this Chinese cohort. We provide detailed
phenotypic and genotypic descriptions of large rare genic CNVs that may represent CHD loci in the East Asian population. Larger
samples of Chinese origin will be required to determine whether the genome-wide distribution differs from that found in
predominantly European CHD cohorts.
npj Genomic Medicine (2016) 1, 16033; doi:10.1038/npjgenmed.2016.33; published online 14 September 2016
INTRODUCTION
Congenital heart diseases (CHDs) are the most common birth
defect and a major cause of morbidity and mortality.1 Conotruncal
heart defects (CTDs) are CHDs affecting the cardiac outﬂow tract.
These include tetralogy of Fallot (ToF), pulmonary atresia with VSD
(PAVSD), truncus arteriosus, interrupted aortic arch, transposition
of the great arteries and double outlet right ventricle. Overall,
CTDs have an estimated prevalence of 11.6 per 10,000 live births.2
Figures available for ToF, the most common CTD, indicate a
prevalence of 2.7 per 10,000 live births in Europe2 and 4.7 per
10,000 live births in the United States.3 In Taiwan, the prevalence
has been reported to be 6.26 per 10,000 live births.4 Although
Hong Kong does not have the prevalence data for CTD, in
terms of the proportion of all CHD, pulmonary outﬂow tract
obstruction alone accounts for 31.1% of all symptomatic Chinese
neonates with CHD in Hong Kong, almost double the proportion
reported in western studies,5 implying that this group of
congenital abnormalities may have greater representation in
Asian populations.
Although it is thought that genetic factors have an important
role in CHD, only about 11% of patients receive a genetic
diagnosis.1 In addition to chromosomal abnormalities and rare
single-nucleotide variants, a growing proportion of the mole-
cular diagnosis is attributed to rare copy-number variations
(CNVs). Multiple studies show an increased burden of rare CNV
in patients affected with ToF compared with controls, and
several recurrent loci have been reported to be pathogenic for
ToF, the most notable being the deletion responsible for
22q11.2 deletion syndrome.6–12 Nevertheless, Chinese studies
are lacking.
Recognising the importance of CTDs in Chinese patients, and
the wide spectrum of CNVs contributing to CTDs in other cohorts,
our aim was to discover important CNVs in a Chinese cohort,
focusing on the large (4500 kb) CNVs, readily detectable on
clinical microarray platforms. We hypothesised that large rare
structural variants that overlap the coding sequence of one or
more genes would be associated with CTDs, over and above the
recurrent 22q11.2 deletion we previously showed to be prevalent
in this cohort.8 We present case examples characterising the
lifetime phenotype of patients harbouring CNVs that are likely to
be the most clinically signiﬁcant.
RESULTS
Patient demographics
The 116 patients (62 males, 54 females) with CTD recruited from
the adult CHD clinic had a mean age± s.d. of 31.0 ± 8.4 years that
showed a normal distribution (range 17–53 years, skewness 0.74,
kurtosis 0.031). All of the patients recruited with CTD had either
ToF (81.9%, n= 95) or PAVSD (18.1%, n= 21).
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Large rare CNVs
Using stringent criteria and methods,10 rare CNV calls were
obtained for 108 (93.2%) of the 116 subjects and therefore these
subjects were used as the CNV discovery cohort. Filtering for only
CNVs found in o1% of platform-matched controls, a total of 306
rare autosomal CNVs were identiﬁed in these 108 subjects. The
subsequent analysis focused on CNVs that were large (deﬁned as
4500 kb), rare (o1% in all platform-matched and ethnicity-
matched control groups, total = 5,902), and overlapped the exons
of genes. Ten large CNVs from ten patients met these criteria
(Table 1). Of note, the sex distribution of these 10 patients was
skewed, with 7 females and 3 males, although the overall cohort
had an excess of male patients. None of the large CNVs identiﬁed
overlapped the smaller (o500 kb) rare CNVs found in the sample
of 108 patients. The clinical features of these 10 patients are
summarised in Table 2.
Clinical cases and candidate genes of signiﬁcant large rare CNVs
Of these 10 CNVs, three were de novo large rare CNVs found
in syndromic patients. First is a large duplication at 2q22.3
(Patient 1), the second, a 5 Mb deletion at 13q33.3 (Patient 9) and
the third, a 611 kb deletion at 17p13.3 (Patient 10). Below we
discuss in detail the phenotypic and molecular features of these
three patients.
2q22.3 duplication overlapping the ZEB2 gene
Patient 1 (female, age 32 years) was born with ToF and patent
foramen ovale. She had mild intellectual disability and adjustment
disorder. She also has a history of dysfunctional uterine bleeding.
On examination, she was dysmorphic, but did not ﬁt the facial
features of Mowat–Wilson syndrome. The most remarkable
observation was that she had a hypernasal voice (Figure 1a).
A de novo 2.1 Mb copy-number gain was found at 2q22.3, which
overlaps the ZEB2 gene. Deletions of this gene are a known cause
of Mowat–Wilson syndrome (OMIM#235730) in which conotruncal
heart disease have been described.13,14 However, there have been
no known reports of a duplication leading to the Mowat–Wilson
syndrome phenotype. Such a large gain in copy-number may
disrupt regulatory elements, such as the expression levels of ZEB2,
which would subsequently affect transcription downstream.
The ZEB2 gene (previously known as ZFHX1B, or SIP1) is widely
expressed in human embryological development, including in the
heart.15 The protein encoded by this gene, is SMAD-interacting
protein-1 (ref. 16), which acts to activate or repress transcription
by binding to regulatory sequences of E-boxes.17 SMAD proteins
are present in the cytoplasm to mediate transforming growth
factor β (TGF-β) signals from receptors of the cell-surface into the
nucleus,18 and hence the TGF-β group of cytokines are likely to
have an important role in embryological development,18 including
cardiac outﬂow tract formation. Loss of ZEB2 in the mouse is
associated with variable heart defects,19 similar to the cardiac
anomalies with deletions of this gene in human Mowat–Wilson
syndrome.
A 13q33.3 deletion in a critical region for CHD
Patient 9 (female, age 21 years) has a complex cardiac anatomy of
dextrocardia, PAVSD, and patent ductus arteriosis. She was born
cyanotic and small for dates, with a birth weight of 2.5 kg.
Neurological assessment up to 8 months was apparently normal,
however, at age 15 months, motor and speech delays were noted.
She also had a brain abscess complicated by focal seizures at age
21 months. The head circumference was below the 3rd centile
even before the occurrence of the brain abscess, however, and
remained at the same percentile after the resolution of this
infection. Subsequently, there was overall slow progress in
intellectual function and the patient had attended a specialT
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school. On examination, she had mild facial dysmorphic features
with low set ears and hypernasal speech (no clinical photos).
In this patient, a large de novo 4.9 Mb deletion was found at
13q33.3, detectable by G-banding karyotype performed after the
microarray. The CNV overlaps 41 genes, some notable among
these were TFDP1, GAS6, COL4A1, COL4A2 and SOX1 (Figure 2).
Given the size, and the known critical region, this CNV was
clinically classiﬁed as pathogenic.
The 13q33.2-33.3 region has previously been proposed to be a
critical region for CHD20,21 (Figure 2). Huang et al. summarised
deletions with different CHD phenotypes such as ToF,
ostium secundum,22 coarctation of the aorta,23 interauricular
communication,23 pulmonary valve stenosis,24 patent ductus
arteriosus,24 ASD/VSD20 and single atrium.20 Looking at cono-
truncal defects only, three cases of ToF have so far been reported
to have very large deletions that overlap this critical region.22,23
McMahon et al. also reported a case of double outlet right
ventricle within this proposed critical region with a 2.5 Mb
deletion at 13q33.3-33.4 (Figure 3).25 They speculated that the
collagen genes COL4A1 and COL4A2 are candidate genes for CHD
as they are likely to have a role in cardiac development. The CNV
found in our patient falls within the proposed critical region, and
has a complex phenotype of PAVSD, dextrocardia, patent ductus
arteriosus and situs solitus. It is interesting that within the small
region of overlap with the CNV reported by McMahon et al. are the
genes COL4A1 and COL4A2, which agrees with their hypothesis.
However, the 13q33.3 deletion of Patient 9 also overlaps a smaller
1.1 Mb deletion with single atrium reported by Yang et al. that did
not include either of these two collagen genes.21 Of note, in our
cohort, there was another large copy-number gain at 13q33.2-33.3
(patient 8), overlapping ﬁve genes (EFNB2, ARGLU1, DAOA-AS1,
DAOA and LINC00460), further suggesting the potential impor-
tance of this region and ephrin-B2 signalling in CHD.26
Summarising all the evidence so far, we posit that deletions of
13q33.3 are strongly associated with CHD but that narrow critical
regions, or candidate genes, remain to be conﬁrmed with
more cases.
17p13.3 deletion telomeric to the critical region of Miller–Dieker
Syndrome (MDS)
Patient 10 (Female, age 27 years) is known to have PAVSD. She
required multiple surgeries, including a left modiﬁed Blalock-
Taussig (LmBT) shunt for left pulmonary artery stenosis at age
7 months. Subsequently, closure of VSD and right ventricular
outﬂow tract reconstruction was performed at the age of 7 years.
She is currently on warfarin due to atrial ﬁbrillation. She had a
history of epilepsy since age 17 years, initially presenting with
petit mal seizures with normal EEG, controlled with sodium
valproate. She studied in a special school because of mild
intellectual disability. Her other medical history includes scoliosis,
left hip dysplasia requiring total hip replacement, severe myopia
and amblyopia, as well as primary amenorrhoea (diagnosed at age
17 years). On examination, she had dysmorphic facial features
(Figure 1b).
The CNV analysis revealed a de novo 611 kb loss at 17p13.3
overlapping 10 genes, including NXN (Figure 3). The NXN gene is
expressed in murine heart and there is evidence that loss of the
NXN gene is associated with CHD in mice.27 In humans, the gene is
expressed in human heart and has a haploinsufﬁciency prediction
score of 37.4%,28 as well as RVIS (Residual Variation Intolerance
Score)29 percentile of 11.77% (i.e., the top 11.77% most intolerant
of human genes to variation). The role of NXN in the canonical
Wnt/β-catenin signalling pathway through regulation of the
dishevelled protein and the gene’s subsequent role in second
heart ﬁeld signalling, further suggest this gene’s potential
involvement in cardiac development.T
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Notably, a similarly sized (544 kb) rare copy-number gain over-
lapping the NXN gene was reported by another group to be
associated with ToF.10 As PAVSD may be considered to be at the
more severe end of the spectrum of the cardiac phenotype in
relation to ToF, the loss of one copy at this locus may implicate a
more profound cardiac developmental effect for CHD than would a
gain of copy. Isolated case reports indicate a link between CHD and
large deletions in this region at the resolution of the chromosome
band, including two from Taiwan and Japan with ToF30 and
PAVSD,31 respectively, that overlap NXN. This suggests that a critical
region for CHD may be located in the region of the NXN gene
(Figure 3), in addition to the more proximal MDS region (Figure 3).
DISCUSSION
Large rare CNVs in conotruncal heart disease
A number of studies have explored the contribution of CNVs to
conotruncal heart defects, particularly ToF. Most of these studies
involved samples from predominantly Caucasian popula-
tions.6,7,9–11,32 Although there is evidence to suggest an increased
burden of large rare CNVs in ToF patients compared with
the normal population,6,10,11 few loci have been found to be
recurrently associated with the disease, implicating substantial
genetic heterogeneity.33 The most notable recurrent CNVs
responsible for ToF are 22q11.2 deletions, followed by 1q21.1
duplications.7,10,11 In this study of adult Chinese patients with
CTDs, after excluding those with recurrent 22q11.2 deletions
(15.3%), we discovered large rare CNVs in 10 of 108 (9.3%)
patients; the previously reported 1q21.1 duplication involving
GJA5 gene was not found.7,10,11 We were able to characterise the
clinical features of these 10 patients by clinical re-evaluation and
determine that three were syndromic. All three of these patients
carried a de novo CNV harbouring genes potentially linked to
cardiac development that would be considered pathogenic. The
other seven large genic CNVs, all very rare and in patients with few
or no reported extracardiac features, would represent variants of
unknown clinical signiﬁcance (VUS). For the two of these seven
with parental samples available the CNVs were inherited, as is
often found for complex developmental conditions.34
Figure 1. Patient facial phenotypes. (a) Patient 1 with 1.8 Mb gain at 2q22.3 involving the ZEB2 gene. (b) Patient 10 with 611 kb loss at 17p13.3
involving the NXN gene. No consent for clinical photos for Patient 9.
Conotruncal heart anomalies
CCY Mak et al
4
npj Genomic Medicine (2016) 16033 Published in partnership with the Center of Excellence in Genomic Medicine Research
Possible ethnic speciﬁc CNV distribution in Chinese
Whist there appears to be some similarities and overlap of CNVs in
our cohort compared with the literature, such as the prevalence of
recurrent 22q11.2 deletions and overlap of deletion at 5q35.3
(Supplementary Information S1), the distribution of other large
rare CNVs in this Chinese CTD cohort seemed to differ to some
extent from the published literature on ToF in the predominantly
Caucasian samples studied. Several publications reported recur-
rent large (over 1 Mb) rare duplications involving the GJA5
gene.7,10,11 Absence of this CNV in our cohort could be due to
insufﬁcient sample size given the ~ 1% prevalence in European
ToF cohorts.7 Alternatively, 1q21.1 duplications may be rarer in
Figure 2. CNVs with conotruncal heart disease in the 13q31-34 region. 1–3—three cases of reported ToF with loss CNVs of approximately 20–
30 Mb (Ballarati et al. and Quelin et al.).22,23 4—deletion in patient with double outlet right ventricle, overlapping genes COL4A1 and COL4A2
(McMahon et al.).25 5—deletion in Patient 9 from the current study with PAVSD, overlapping genes COL4A1 and COL4A2. 6—deletion in patient
with single atrium (Yang et al.).21 7—duplication in Patient 8 from the current study with PAVSD. 8—CHD critical region proposed by Huang
et al.20
Figure 3. CNVs associated with congenital heart disease in the 17p13.2-13.3 region and relationship to the Miller–Dieker Syndrome (MDS)
Critical Region. Deletion in Patient 10 in this study overlapping the NXN gene. Deletion in patient with PAVSD, overriding aorta and PDA
(Kowase et al.).31 Deletion in patient with Tetralogy of Fallot (Chen et al.).30 Deletion in DECIPHER Patient 4,350 with PDA, PS. Deletion in
patient with PDA (Serrenath Nagamani et al. 2009, patient 5). Deletion in patient with PDA, Pulm Hypertension (Shiff et al. 2010, patient B).
Duplication in patient with ToF, CNV also overlapping NXN gene (Silversides et al., Case 34).10 Overlapping region of CNV in Patient 10 with
other large deletions associated with CHD, a possible critical region for CHD expression. Previously proposed critical region for MDS within the
region of genes YWHAE and PAFAH1B1 (Cardoso et al.).50
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East Asian populations. It is known that there can be considerable
stratiﬁcation of recurrent rearrangements between Asian and
European populations,35 and this may be the case for 1q21.1
duplications. Despite our study being the largest Chinese cohort
of CTD reported to date, a larger sample sizes will be needed to
determine whether 1q21.1 CNVs are truly rarer in individuals of
Chinese origin than in those of European descent.
With respect to the rare de novo CNVs found, we speculate that
CNVs in the greater 17p13.3 region may be an important cause of
developmental disorders in the Chinese population. In general,
CNVs in this region are non-recurrent and may lead to various
phenotypes other than that of typical MDS. Supporting this
possibility, our group has reported cases of 17p13.3 duplication
(with aortic stenosis, microcephaly and dysmorphism)36 and
triplication (with split-hand malformation)37 in Hong Kong. Larger
studies of the Chinese population will be needed to better classify
pathogenic CNVs in the 17p13.3 region, and to determine whether
there are any ethnic differences in prevalence.
Advantages and limitations
Our study was carried out using two large groups of European
controls,10 and one of Chinese controls,38 to adjudicate rarity of
CNVs. The array platform and stringent criteria used for CNV
calling have also been validated before.10 Another advantage of
this study is the utilisation of an adult cohort with the availability
of long-term medical information. Data regarding both develop-
ment and later medical complications could be obtained as a
result, giving us more information on the potential phenotypic
effects of these large rare CNVs over a long period of time.
Performing this study on Han Chinese exclusively also meant that
we could better begin to characterize the distribution of CNVs
related to CHD in this ethnic group, as well as provide
documentation of the clinical presentation for reference. Never-
theless, despite being the largest Chinese study so far of CNVs in
CHD, our sample size was not sufﬁcient for CNV burden analysis.
Furthermore, not all parental samples were available for
determination of de novo status of these CNVs.
CONCLUSION
This study of 116 Chinese patients with conotruncal heart defects
identiﬁed ten large (4500 kb) rare genic CNVs, three of which
were determined to be de novo and pathogenic and the others of
less certain clinical signiﬁcance. Notably, we did not ﬁnd the
previously reported recurrent 1q21.1 duplication in our cohort.
Figure 4. Study protocol for CNVs associated with conotruncal anomalies.
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The small sample size precludes concluding whether or not the
distribution of rare CNVs differs in the Chinese population from
that observed in European populations. We also provide further
evidence for the pathogenicity of the 17p13.3 and 13q33.3 loci,
involving the candidate genes COL4A1 and COL4A2, and NXN,
respectively.
MATERIALS AND METHODS
Patients and samples
A summary of the study design is provided in Figure 4. Adult patients
(418 years of age) with CTDs, but no prior genetic diagnosis, were
prospectively recruited between February 2012 to July 2013 from the adult
congenital heart disease clinic at Queen Mary Hospital, the only tertiary
referral centre for CHDs in Hong Kong. All patients were self-reported to be
Han Chinese. On a research basis, patients were identiﬁed by the attending
cardiologist and recruited if a diagnosis of congenital CTD had been
recorded. The diagnoses were determined from previous cardiology clinic
notes, echocardiograms and operation records based on the cardiologist’s
experience. The standard care of these patients with CHD in Hong Kong
does not involve any genetic testing. Using protocols approved by the
local institutional review board, written informed consent was obtained for
quantitative ﬂuorescence PCR (QF-PCR), chromosomal genome-wide
microarray analysis and publication of photos (Patient 1 and Patient 10).
Genomic DNA was extracted from whole blood samples. Patients were
ﬁrst screened for 22q11.2 deletions by QF-PCR followed by conﬁrmatory
ﬂuorescence in situ hybridisation (FISH) using a standard probe.8 Patients
tested 22q11.2 deletion positive8 (n=21 of 137, 15%) were excluded. We
included only the patients with ToF or PAVSD and excluded further two
cases with persistent truncus arteriosus (n=1) and interrupted aortic
arch (n=1) respectively for a more homogenous discovery cohort.
Samples were sent for CNV analysis at The Centre for Applied Genomics
(The Hospital for Sick Children, Toronto, ON, Canada) using the Affymetrix
6.0 SNP array.
Stringent CNV calling criteria and control groups
Using multiple CNV calling algorithms (Birdsuite,39 iPattern40 and
Affymetrix Genotyping Console), a stringent criteria was used to call the
CNVs,10 i.e., at least 10 kb in length, spanning 5 or more consecutive array
probes and called by more than one algorithm. We compared CNVs
identiﬁed to two different groups of population controls and deﬁned rare
CNVs as those with a population frequency of o1% using a 50% reciprocal
overlap criterion. First, we compared with CNVs analysed in the same way
from 3,957 platform-matched controls,10 which included CNVs from the
Ottawa Heart Institute Coronary Heart Disease Study, n= 1,234; German
PopGen Project, n= 1,123;41 the Ontario Population Genomics Platform,
n= 416;10 and Hapmap3 Project,42 n= 1,184. As individuals of Chinese
ancestry only formed a small proportion (4.8%) of these controls, as a
second stage, we compared CNVs to 1,945 Chinese subjects from the
Singapore SgD-CNVdatabase38 in an attempt to eliminate variants with a
frequency 41% that were speciﬁc to the Chinese population.
Interpretation of CNVs
Our analysis prioritised large (4500 kb) CNVs that overlapped genes since
these are more likely to be of clinical signiﬁcance. CNVs not observed in
any of the total 5,902 controls were classiﬁed as very rare. Only autosomal
CNVs were examined.
The pathogenicity of the CNVs in relation to CTD was analysed
systematically using online databases. Each CNV and gene was manually
interrogated for the likelihood of causing a cardiac disease phenotype. The
databases used for CNV analysis included Database of Genomic Variants
(DGV),43 Online Mendelian Inheritance in Man (OMIM), Decipher44 and
ISCA.45 Each gene overlapped by the CNV was studied using evidence from
PubMed, OMIM, Mouse Genome Informatics (MGI)46 and ZFIN47 to
elucidate any potential relevance to congenital heart anomalies and
identiﬁed as candidate genes. Genomic parameters used were from
GRCh37/hg19.
Validation of clinically relevant CNVs
CNVs classiﬁed as putatively clinically relevant were validated using
NimbleGen CGX-135K oligonucleotide array (Signature Genomics, Roche
NimbleGen, Madison, WI, USA) or 60K CGX v.2 oligonucleotide array
(manufactured by Agilent Technologies, Santa Clara, CA, USA; PerkinElmer,
Turku, Finland), as described previously48 and by the manufacturers. These
microarray platforms were used for clinical diagnostic purposes in our
institution. The former NimbleGen array has an average resolution of
140 kb, with a higher resolution (40 kb or less) in regions thought to be of
signiﬁcance in human development, while the latter Agilent array has an
average resolution 190 kb with a higher resolution of 28 kb in the
respective regions of focus. The Genoglyphix software (Signature
Genomics, Spokane, WA, USA) was used to analyse and annotate the
results. Only a limited number of parental samples were obtained when
calling back the patients, and trio aCGH testing was offered where
possible. Several large rare CNVs detected on the Affy 6.0 platform could
not be validated by the NimbleGen CGX-135K platform or quantitative
real-time PCR. These CNVs were either in regions of high density of
segmental duplications or in close proximity to the centromere. To
eliminate these false positives, all large rare CNVs with 470% segmental
duplications overlap or near the centromere (e.g., 4p11) were also
excluded from this study.
Detailed phenotyping of patients with large, rare CNVs
Patients with potentially clinically relevant CNVs were called back for
reassessment by a geneticist and given genetic counselling by a genetic
counsellor. Lifetime medical history was reviewed and examination was
performed for these patients to systematically characterize any syndromic
(two out of three features of learning difﬁculties, global dysmorphic facial
features, hypernasal voice49) or other extracardiac features. This encom-
passed birth history, medical history including thyroid function, hearing
and immunodeﬁciency, as well as speech, learning and behavioural
difﬁculties. A family history of CHD, intellectual disability and congenital
anomalies was also obtained.
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